Showing 871-880 of 1211 results for "".
- Migraine-Associated Photophobia Appears to Improve After Botulinum Toxin A Injectionshttps://modernod.com/news/migraine-associated-photophobia-appears-to-improve-after-botulinum-toxin-a-injections/2479703/Photophobia in patients with migraine improves following botulinum toxin A injections, according to results from an observational study, as reported in Reuters. Photophobia and dry eye symptoms are common in patients with migraine,
- Nacuity Pharmaceuticals Achieves Target Enrollment for Phase 1/2 Clinical Trial of NPI-001 for the Treatment of RP Associated with Usher Syndromehttps://modernod.com/news/nacuity-pharmaceuticals-achieves-target-enrollment-for-phase-12-clinical-trial-of-npi-001-for-the-treatment-of-rp-associated-with-usher-syndrome/2481641/Nacuity Pharmaceuticals announced that target enrollment of 48 patients has been reached in the SLO-RP phase 1/2 clinical trial of NPI-001 tablets in patients with retinitis pigmentosa (RP) associated with Usher syndrome (USH). “We are pleased to reach our target enrollment,
- Atsena Therapeutics Announces Positive Results from Phase 1/2 Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)https://modernod.com/news/atsena-therapeutics-announces-positive-results-from-phase-iii-clinical-trial-of-atsn-101-for-the-treatment-of-gucy2d-associated-leber-congenital-amaurosis-lca1/2481145/Atsena Therapeutics announced positive results from the phase 1/2 clinical trial of ATSN-101, its lead investigational gene therapy product formerly known as SAR439483, for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). The data demonstrated that su
- New Combined Data from the Phase 2 and Phase 3 Teprotumumab Clinical Trials to be Presented during the American Thyroid Association Annual Meetinghttps://modernod.com/news/new-combined-data-from-the-phase-2-and-phase-3-teprotumumab-clinical-trials-to-be-presented-during-the-american-thyroid-association-annual-meeting/2477038/New pooled data from the phase 2 and phase 3 clinical trials of teprotumumab, an investigational medicine being developed by Horizon Therapeutics, will be presented during an oral plenary presentation at the 89th Annual Meeting of the American Thyroid Association (ATA) in Chicago on Oc
- Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in GAhttps://modernod.com/news/annexon-presents-new-neuroprotection-data-showing-anx007-protects-vision-and-vision-associated-structures-in-ga/2482268/Annexon presented new analyses of ANX007 from the phase 2 ARCHER trial in geographic atrophy (GA), and new preclinical data on the role of C1q in the pathogenic elimination of photoreceptor synapses and their protection with C1q blockade in GA. ANX007 is a first-in-class, non-pegylated
- Aviceda Submits Investigational New Drug Application for AVD-104 for the Treatment of GA Associated with AMDhttps://modernod.com/news/aviceda-submits-investigational-new-drug-application-for-avd-104-for-the-treatment-of-ga-associated-with-amd/2481477/Aviceda Therapeutics announced that it has submitted an investigational new drug (IND) application to the FDA. The IND supports the use of its lead intravitreal ocular asset, AVD-104 (a novel glycan-coated nanoparticle), for the treatment of GA secondary to AMD. Aviceda previously announced
- Atsena Therapeutics to Present Positive Phase 1/2 Clinical Trial Data of ATSN-101 for the Treatment of GUCY2D-Associated LCA1https://modernod.com/news/atsena-therapeutics-to-present-positive-phase-12-clinical-trial-data-of-atsn-101-for-the-treatment-of-gucy2d-associated-lca1/2481394/Atsena Therapeutics announced that positive interim data from the ongoing phase 1/2 clinical trial of ATSN-101 will be presented at the 46th Annual Macula Society Meeting, which is being held February 15-18 in Miami. This is an encore presentation of data that were presented as a l
- Microinvasive Glaucoma Surgery with the OMNI Surgical System is Associated with Diminished Diurnal IOP Fluctuationshttps://modernod.com/news/microinvasive-glaucoma-surgery-with-the-omni-surgical-system-is-associated-with-diminished-diurnal-iop-fluctuations/2480463/Sight Sciences announced publication in
- Bausch + Lomb and Clearside Biomedical Announce FDA Approval of Xipere for the Treatment of Macular Edema Associated with Uveitishttps://modernod.com/news/bausch-lomb-and-clearside-biomedical-announce-fda-approval-of-xipere-for-the-treatment-of-macular-edema-associated-with-uveitis/2480374/
- Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meetinghttps://modernod.com/news/aerie-pharmaceuticals-announces-presentations-at-the-2021-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting/2479128/Aerie Pharmaceuticals, an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases, announced it will participate and have poster